Literature DB >> 33418504

How to select cancer patients for immunotherapy.

Per Pfeiffer1, Camilla Qvortrup2, Karin Holmskov Hansen3.   

Abstract

Entities:  

Year:  2021        PMID： 33418504      PMCID： PMC7804597          DOI： 10.1016/j.ebiom.2020.103184

Source DB:  PubMed          Journal:  EBioMedicine        ISSN： 2352-3964            Impact factor:   8.143


× No keyword cloud information.
  5 in total

Review 1.  Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.

Authors:  Michael J Duffy; John Crown
Journal:  Clin Chem       Date:  2019-07-17       Impact factor: 8.327

2.  Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis.

Authors:  Chia Ching Lee; Yu Yang Soon; Jeffrey Huey Yew Lum; Char Loo Tan; Jeremy Chee Seong Tey
Journal:  Acta Oncol       Date:  2020-03-20       Impact factor: 4.089

3.  Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.

Authors:  Bin Zhao; Hong Zhao; Jiaxin Zhao
Journal:  Ther Adv Med Oncol       Date:  2020-07-16       Impact factor: 8.168

4.  Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A multidimensional analysis.

Authors:  Yutian Zou; Xiaoqian Hu; Shaoquan Zheng; Anli Yang; Xing Li; Hailin Tang; Yanan Kong; Xiaoming Xie
Journal:  EBioMedicine       Date:  2020-12-10       Impact factor: 8.143

5.  Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.

Authors:  Xian Shen; Bin Zhao
Journal:  BMJ       Date:  2018-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.